Lima Memorial receives echocardiography recognition
This achievement demonstrates Lima Memorial's long-term commitment to continuously improving patient outcomes and safety with echocardiography.
Every three years, accredited facilities like Lima Memorial undergo an application and review process to re-earn accreditation, according to the press release.
"Reaching the Silver Milestone for 25 years of service is a remarkable achievement and a testament to the consistent, high-quality care and safety our patients and their families can count on," said Brian Scheid, director of cardiopulmonary services, in a press release.
Echocardiography is used to assess different areas of the heart and can detect heart disease or signs of serious cardiovascular conditions.
Reach Cade Higgins at 567-242-0351
Featured Local Savings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30-04-2025
- Yahoo
Lima Memorial receives echocardiography recognition
Apr. 30—LIMA — Lima Memorial Health System received the Silver Milestone Recognition from the Intersocietal Accreditation Commission after achieving accreditation for more than 25 years, according to a press release. This achievement demonstrates Lima Memorial's long-term commitment to continuously improving patient outcomes and safety with echocardiography. Every three years, accredited facilities like Lima Memorial undergo an application and review process to re-earn accreditation, according to the press release. "Reaching the Silver Milestone for 25 years of service is a remarkable achievement and a testament to the consistent, high-quality care and safety our patients and their families can count on," said Brian Scheid, director of cardiopulmonary services, in a press release. Echocardiography is used to assess different areas of the heart and can detect heart disease or signs of serious cardiovascular conditions. Reach Cade Higgins at 567-242-0351 Featured Local Savings
Yahoo
23-03-2025
- Yahoo
OSU, Lima Memorial hold Heart Summit
Mar. 22—LIMA — The room was filled with the sound of pens clicking and notes being written as attendees listened to various faculty members presenting the latest advancements in the treatment, diagnosis, and management of cardiovascular disease at the seventh annual Heart Summit. Twelve presentations were offered by Lima Memorial Health System and Ohio State University doctors in the Science and Life building at Ohio State University's Lima campus, 4240 Campus Drive, continuing a strong, efficient and collaborative affiliation. "It really allows us to interact with primary care and cardiology physicians, nurse practitioners and nurses themselves here in the community so they're aware of some of the things that are coming forward," Dr. Ralph Augostini, a clinical cardiac electrophysiology, cardiovascular disease, physician and a clinical professor of internal medicine at Ohio State University, said. "We come to (Lima) Memorial to interact with patients in terms of procedural care, to do things like device implant or replacement as well as cardiac electrophysiology studies." Augostini delivered a presentation about device therapy for obstructive and central sleep apnea. "Both obstructive and central apnea are burdened by chronic fatigue, poor quality of life and negative outcomes," Augostini said. "Inspire (sleep apnea device) is really a secondary option with use of CPAP (continuous positive airway pressure) therapy first." Dr. Pamela Gardner, congestive heart failure clinic director at Lima Memorial Health System touched on how the affiliation between Lima Memorial and Ohio State University has made contact quicker. "I have on speed-dial the individual for that particular problem so I can contact somebody," Gardner said. "I don't have to go through a transfer center where we talk to some secretary that then tracks somebody down, I can directly speak to that particular specialty." Gardner spoke about danger shock and protocol management of cardiac shock. Other presentation topics included structural heart innovations, electrocardiogram tests, remote monitoring, syncope evaluation, atrial fibrillation, conduction system pacing, glicagon-like peptide-1s, heart failure management and aortic valve stenosis. Reach Cade Higgins at 567-242-0351. Featured Local Savings
Yahoo
21-11-2024
- Yahoo
Hyperfine Swoop® Portable MR Brain Imaging System Meets New Standards Recently Issued by CMS-Approved Accrediting Body
The Swoop® Portable MR Imaging® System (Photo: Business Wire) Intersocietal Accreditation Commission (IAC)'s release of new standards accepting ultra-low-field MRI technology enables accredited facilities to qualify for reimbursement from the US Centers for Medicare & Medicaid Services (CMS). GUILFORD, Conn., November 21, 2024--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the issuance of new MRI standards by the Intersocietal Accreditation Commission (IAC), a leading CMS-approved accrediting body. The new standards, effective immediately, now include portable MR scanning at the point of care. The IAC, a nonprofit accrediting organization dedicated to quality improvement and patient safety, has updated its advanced imaging standards to incorporate ultra-low-field MRI technology. The updated IAC Standards and Guidelines for MRI Accreditation addresses new technology that allows point-of-care service for MRI brain exams. This change enables IAC-accredited facilities and medical offices in the US to qualify for CMS reimbursement for brain scans performed using the Swoop® system. The compact and versatile Swoop® Portable MR Imaging® system is designed for use in any professional healthcare setting, including medical offices. Its ultra-low field strength of 0.064T eliminates the need for costly shielded MRI rooms. Its plug-and-scan functionality and user-friendly tablet interface enable medical staff to easily operate the system. "The new IAC guidelines, which outline personnel, training, and safety requirements for MRI accreditation, pave the way for the Swoop® system to be available in neurology offices and clinics," said Maria Sainz, President and CEO of Hyperfine. "With IAC accreditation, physicians can now obtain diagnostic-quality MR brain images within their clinics, providing patients with timely and convenient MRI access at the point of care." For more information about the Swoop® Portable MR Imaging® system, please visit About the Swoop® Portable MR Imaging® System The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets. Story Continues About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. View source version on Contacts Media Contact Dana Schroeder Health+Commerce dana@ Investor Contact Marissa Bych Gilmartin Group LLC marissa@
